TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04669158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
Study: NCT05422326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo on Day 22
Description: Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
Study: NCT05156918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will rotate between three exercise machines (randomly assigned rotation order at outset): A Concept C2 rowing machine, a stationary bicycle, and a treadmill. Study participants will use a different machine each day so that they are using each of the three exercise machines once per week. Two treadmills, two bikes, and two rowers are available during each exercise session. Participants will be randomly assigned to one of three machine orders: treadmill-rower-bike, rower-bike-treadmill, or bike-treadmill-rower. We will employ a percent of heart rate protocol as an exercise intensity measure (77-93% of age-adjusted maximum heart rate) rather than a less well-defined maximal effort protocol or rating of perceived exertion scale. For the purposes of this exercise protocol high intensity exercise will be defined as 77-93% of age adjusted maximum heart rate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Exercise
Description: There are no modifications to regular diet or exercise habits for 30 days.
Study: NCT04783467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE) Schedule
Description: \[See arm/group descriptions\]
Study: NCT05536349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Given by PO
Study: NCT04871789

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory and instrumental examination
Description: All patients will undergo a comprehensive examination to identify the consequences of COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory and instrumental examination
Description: All patients will undergo a comprehensive examination to identify the consequences of COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory and instrumental examination
Description: All patients will undergo a comprehensive examination to identify the consequences of COVID-19
Study: NCT05824026

Intervention type: DEVICE
Group type: OTHER
Intervention: Gelling fiber wound dressing with silver
Description: intervention involving a wound dressing with silver
Study: NCT05830955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lullaby group
Description: The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast milk group
Description: The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
Study: NCT06580145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-leucine
Description: L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-lysine
Description: L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally
Study: NCT05456308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
Study: NCT06495619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment-as-usual
Description: life style modification intervention for weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: combined TAU and guided self-help
Description: combined TAU and guided self-help for improving eating behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: combined TAU, GSH, and biofeedback
Description: combined TAU, GSH, and biofeedback for improving eating behaviors and interoceptive awareness and arousal regulation
Study: NCT04526366

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure device deployed for at least one night synchronously with polysomnography.

Intervention type: DEVICE
Intervention: Polysomnography
Description: Polysomnography deployed for at least one night synchronously with Continuous Positive Airway Pressure.
Study: NCT04588961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy with suspensionplasty
Description: Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint alloplasty
Description: Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
Study: NCT05640349

Intervention type: BIOLOGICAL
Intervention: Positive blood culture
Description: Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic

Intervention type: BIOLOGICAL
Intervention: Positive blood culture
Description: Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic
Study: NCT04594031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Description: Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ \>1x10E6/kg)
Study: NCT06089577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor 50 MG
Description: Cangrelor will be administered during PCI
Study: NCT06300229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Subcutaneous injection with 60 mg Denosumab once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Subcutaneous injection with NaCl once
Study: NCT06636877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019-2
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1019-3
Description: One tablet administered alone
Study: NCT06582277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836 shot
Description: One single administration intramuscularly at Day 1.
Study: NCT05456308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
Study: NCT05169164

Intervention type: OTHER
Intervention: No intervention, observational
Description: No intervention, observational
Study: NCT05994456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: 240mg, Q3W. The opportunity for surgery was evaluated after 2 cycles of treatment and surgical treatment was performed after 2-4 cycles of treatment. Postoperatively, adjuvant therapy was continued according to the neoadjuvant regimen, and direct treatment met the criteria for termination of treatment.
Study: NCT06278285

Intervention type: OTHER
Group type: OTHER
Intervention: Blood GLP1
Description: On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues

Intervention type: OTHER
Group type: OTHER
Intervention: Blood No treated GLP1
Description: On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
Study: NCT06044636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digi-physical breastfeeding support
Description: * Breastfeeding support after birth is provided via chat~* Extended home visits by a pediatric nurse after discharge from the maternity ward~* Extra support from a lactation counselor when needed after discharge until one year after childbirth
Study: NCT05456308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrodistention during cystoscope
Description: Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
Study: NCT04893785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib and Temozolomide
Description: Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner.
Study: NCT05756348

Intervention type: DEVICE
Group type: OTHER
Intervention: Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant
Description: All participants will receive both device interventions listed above.
Study: NCT05004857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book reading
Description: Prior to the first session, a research assistant will place electrodes on the infant and mother so that they study team can gather autonomic nervous system (ANS) response (sympathetic and parasympathetic) non-invasively using MindWare Portable Lab System (MindWare Technologies, Gahanna, Ohio). These electrodes will remain on the infant and mother throughout each session and be removed via adhesive removing pads following each session's data collection. This will minimize discomfort to both parties secondary to electrode removal and minimize risk of skin irritation by leaving electrodes in place for a prolonged period of time. Additional observational data before and after the reading sessions will be collected by the research assistant, including but not limited to: where the session is conducted (mother's arms, bassinet), activity level, vital signs, and any other observed behaviors throughout the session.
Study: NCT06316583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TrP-DN and Acupuncture
Description: Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TrP-DN and Acupuncture
Description: Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TrP-DN and Acupuncture
Description: Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.
Study: NCT06528249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Description: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Description: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Study: NCT04822662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epilepsy Education Programme
Description: Firstly the Child Introduction Form and Parent Information Form were applied. Then the Child's Attitude Towards Self-Disease Scale, Seizure Self-Efficacy Scale for Children, Quality of Life Scale for Children were filled to children. Nurse-Parent Support Scale were applied to the parents in the Pretest and Post Test data.
Study: NCT05633940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of the service delivery model primary care behavioral health
Description: The research project will study a real-world implementation of PCBH in routine primary care. The implementation is facilitated by a regional implementation group of psychologists with special training in PCBH. The active implementation period for each intervention center is 12 months, where continuous support, materials and training are offered by the implementation group.
Study: NCT05679102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 MG Oral Tablet
Description: one group will be given only Amlodipine 5MG once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet
Description: one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily
Study: NCT05510193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktio prosthesis
Description: Transradial myoelectric prosthesis
Study: NCT05101863

Intervention type: BEHAVIORAL
Intervention: Motivational interviewing
Description: MI is a goal-oriented style of communication, and focuses on resolving a patient's ambivalence, while eliciting his/her own reasons to change addictive behavior, also known as change talk.

Intervention type: BEHAVIORAL
Intervention: Motivational interviewing
Description: MI is a goal-oriented style of communication, and focuses on resolving a patient's ambivalence, while eliciting his/her own reasons to change addictive behavior, also known as change talk.

Intervention type: BEHAVIORAL
Intervention: Motivational interviewing
Description: MI is a goal-oriented style of communication, and focuses on resolving a patient's ambivalence, while eliciting his/her own reasons to change addictive behavior, also known as change talk.
Study: NCT04763837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraureteral stent
Description: This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Double-J stent
Description: This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.
Study: NCT05614349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid
Description: This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other
Description: Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other
Description: As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.